Publications Database

Tsai L. Y. (1999)

Psychopharmacology in autism.

Psychosomatic Medicine

61(5), pp. 651-665

Read Abstract (New Window) Read Full (New Window)

Tuchman R. F. (2004)

AEDs and psychotropic drugs in children with autism and epilepsy.

Mental Retardation and Developmental Disabilities Research Reviews

10(2), pp. 135-138

Read Abstract (New Window)

Tyrer P. et al. (2008)

Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial.

Lancet

371(9606), pp. 57-63.

Read Abstract (New Window)

Unwin G. L. , Deb S. (2008)

Use of medication for the management of behavior problems among adults with intellectual disabilities: a clinicians' consensus survey.

American Journal of Mental Retardation

113(1), pp. 19-31

Read Abstract (New Window)

Valdovinos M. G. et al. (2002)

Multimodal evaluation of risperidone for destructive behavior: functional analysis, direct observations, rating scales, and psychiatric impressions.

Experimental and Clinical Psychopharmacology

10(3), pp. 268-275

Read Abstract (New Window)

Valicenti-McDermott M. R. , Demb H. D. (2006)

Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities.

Journal of Child and Adolescent Psychopharmacology

16(5), pp. 549-560

Read Abstract (New Window)

Varni J. W. et al. (2012)

Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: A post hoc analysis of two controlled trials.

Clinical Therapeutics

34(4), pp. 980-992.

Read Abstract (New Window)

Vercellino F. et al. (2001)

Open-label risperidone treatment of 6 children and adolescents with autism

Canadian Journal of Psychiatry

August, 46(6), pp.559-560.

Vitiello B. et al. (2005)

Assessment of the integrity of study blindness in a pediatric clinical trial of risperidone.

Journal of Clinical Psychopharmacology

25(6), pp. 565-569

Read Abstract (New Window)

Vo L. C. et al. (2016)

No apparent cardiac conduction effects of acute treatment with risperidone in children with autism spectrum disorder.

Perceptual and Motor Skills

December, 26(10), pp. 900-908

Read Abstract (New Window)

Weeden M. , Ehrhardt K. , Poling A. (2009)

Conspicuous by their absence: Studies comparing and combining risperidone and applied behavior analysis to reduce challenging behavior in children with autism.

Research in Autism Spectrum Disorders

pp. 905-912.

Read Abstract (New Window)

West L. , Waldrop J. , Brunssen S. (2009)

Pharmacologic treatment for the core deficits and associated symptoms of autism in children.

Journal of Pediatric Health Care

23(2), pp. 75-89

Read Abstract (New Window)

Williams S. K. et al. (2006)

Risperidone and adaptive behavior in children with autism.

Journal of the American Academy of Child and Adolescent Psychiatry

45(4), pp. 431-439

Read Abstract (New Window) Read Full (New Window)

Wink L. K. et al. (2017)

Brief report: Metformin for antipsychotic-induced weight gain in youth with autism spectrum disorder.

Journal of Autism and Developmental Disorders

July, 47(7), pp. 2290–2294.

Read Abstract (New Window)

Wink L. K. , Erickson C. A. , McDougle C. J. (2010)

Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders.

Current Treatment Options in Neurology

12(6), pp. 529-538.

Read Abstract (New Window)

Witwer A. N. , Lecavalier L. (2005)

Treatment incidence and patterns in children and adolescents with autism spectrum disorders.

Journal of Child and Adolescent Psychopharmacology

5(4), pp. 671-681

Read Abstract (New Window)

Wong S. et al. (1991)

Applying a DRO schedule and compliance training to reduce aggressive and self-injurious behavior in an autistic man: a case report.

Journal of Behavior Therapy and Experimental Psychiatry

22(4), pp. 299-304

Read Abstract (New Window)

Zarcone J. R. et al. (2001)

Effects of risperidone on aberrant behavior of persons with developmental disabilities: I: A double-blind crossover studies using multiple measures.

American Journal on Mental Retardation

November, 106(6), pp. 525-538.

Read Abstract (New Window)

Zuddas A. et al. (2000)

Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation.

Journal of Child and Adolescent Psychopharmacology

10(2), pp. 79-90

Read Abstract (New Window)

Mind (2012)

Making sense of antipsychotics.

London: Mind

Read Full (New Window)